Molecular Genetics of Renal Cell Tumors: A Practical Diagnostic Approach

Alaghehbandan, Reza; Montiel, Delia Pérez; Luís, A.; Hes, Ondřej

doi:10.3390/cancers12010085

Cited by 23 publications

(13 citation statements)

References 168 publications

(174 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…RCC is an immunogenic tumor characterized by frequent invasion of tumor tissues by immune cells, rare spontaneous regression, and a clinical response to immunotherapy ( 1 ). The most aggressive RCC in adults is kidney renal clear cell carcinoma (KIRC) ( 2 ). Genetic aberrations and the tumor environment have been indicated to be associated with KIRC.…”

Section: Introductionmentioning

confidence: 99%

Interaction of RARRES1 with ICAM1 modulates macrophages to suppress the progression of kidney renal clear cell carcinoma

Geng

Chi²,

Liu³

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

BackgroundRARRES1 is a tumor suppressor protein, and its expression is suppressed in various tumor cells. However, whether it participates in the immune response in kidney renal clear cell carcinoma (KIRC) is unknown, and the defined mechanism is not clear. Therefore, the mechanism of RARRES1 in KIRC is worthy of investigation.MethodsWe analysed the expression and function of RARRES1 with The Cancer Genome Atlas (TCGA) database. The Kaplan–Meier curve was adopted to estimate survival. RARRES1-correlated genes were obtained from the UALCAN database and subjected to Gene Ontology (GO) enrichment and protein–protein interaction (PPI) network analyses. The correlation analysis between tumor-infiltrating immune cells and selected genes were performed with TIMER database. We also investigated the possible function of RARRES1 in KIRC by coculturing Caki-1 cells with THP-1 cells. Immunofluorescence assay was performed to study the RARRES1 expression in difference grade KIRC tissues.ResultsThe expression of RARRES1 was negatively correlated with survival in KIRC patients. The GO biological process term most significantly enriched with the RARRES1-correlated genes was regulation of cell adhesion. ICAM1, which exhibited a relatively highest correlation with RARRES1, is positively correlated with the infiltration level of macrophages. RARRES1 could enhance the expression of ICAM1 in Caki-1 cells and then induce the activation of M1 THP-1 cells to decrease the viability and induce the apoptosis of Caki-1 cells.ConclusionRARRES1 plays an antitumor role by promoting ICAM1 expression and inducing the activation of M1 macrophages. We offer insights into the molecular mechanism of KIRC and reveal a potential therapeutic target.

show abstract

Section: Introductionmentioning

confidence: 99%

Interaction of RARRES1 with ICAM1 modulates macrophages to suppress the progression of kidney renal clear cell carcinoma

Geng

Chi²,

Liu³

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Moreover, the increasing knowledge about the functions of miRNAs in the pathogenesis of cancers may give remarkable clue for the determination of potential diagnostic biomarkers and therapeutic targets for RCC. It appears that identification of disease-specific miRNAs may help to better clarify prognostic and therapeutic aspects of renal cell carcinomas [19,20]. For these reasons, identification of molecular biomarkers for early diagnosis, the surveillance of RCC treatments and classification becomes more of an issue.…”

Section: Resultsmentioning

confidence: 99%

Analysis of miRNA-Mediated ceRNAs In The Pathogenesis of Renal Cell Carcinoma: An In Silico Approach

Avşar

2020

Hittite J. Sci. Eng.

View full text Add to dashboard Cite

R enal cell tumors represent approximately 3% of all cancers in males and lower incidence in females. Several factors such as genetics, obesity, tobacco smoking, hypertension, diuretics, medications such as acetaminophen and non-aspirin non-steroidal anti-inflammatory drugs, viral hepatitis, and chemical carcinogens (asbestos, arsenic, etc.,) are implicated in the pathogenesis of renal cell tumors [1, 2, 3]. Renal cell carcinomas are divided into three subtypes: chromophobe, renal clear cell carcinoma and renal papillary cell carcinoma and this classification is verified by genetic and cytogenetic analysis [4, 5]. The most common form of renal cell tumors (approximately 70% of renal tumors) is renal clear cell carcinoma in adults. Papillary renal cell carcinoma is the second most frequent kidney tumors in adults [6].

show abstract

“…Recent molecular studies of tubulocystic renal cell carcinomas have demonstrated combined losses at chromosome 9 and gains at chromosome 17, as well as the loss of chromosome Y (in 5/5), and this mutational profile is very characteristic of TCRCC and distinct from other renal neoplasms. [12][13] In contrast, papillary RCC (type 1) demonstrates polysomy or trisomy of chromosomes 7 or 17 as the most frequent changes, while the mutation of MET is uncommon at least in the sporadic ones (14). Thus, the occurrence of tubulocystic RCC and papillary RCC together in the same patient must be addressed as a primary renal collision tumour as both are distinctly separate entities.…”

Section: Discussionmentioning

confidence: 99%

Early Occurrence of Two Distinct Histological Types of Renal Cell Carcinoma in End-Stage Renal Disease Patient on Haemodialysis

Parkhi¹,

Sekar²,

Parmar³

et al. 2020

Ann of Pathol and Lab Med

View full text Add to dashboard Cite

Background: The occurrence of renal cell carcinoma is a well-known complication in end-stage renal disease on haemodialysis. Various histological types of renal cell carcinomas are observed in these patients and varies with the duration of haemodialysis. Though the synchronous association of two renal cell carcinomas in the patients are known, the existence of such dual renal tumours in the patient on dialysis is extremely rare and unheard in the English literature. Moreover, tubulocystic renal cell carcinoma is rarely reported in this setting. Case report and Discussion: We describe an unusual early synchronous occurrence of two tumours with distinct histology i.e. Papillary renal cell carcinoma (PRCC, type I) and Tubulocystic renal cell carcinoma (TC-RCC) in a patient with end-stage renal disease on haemodialysis for a duration less than a year. Though exact etiological factors peculiar to the occurrence of these tumours are not known, increased oxidative stress occurring in end-stage renal disease patient on haemodialysis might play an important role in carcinogenesis. Conclusion: Renal cell carcinoma with more than one histological type may occur exceedingly early without any symptoms in these patients. Radiologists and urologists should be aware of it for early diagnosis and prompt treatment. Pathologists should also be more cautious while grossing and pick the sub-centimetric primary or secondary tumours that may have an impact on patient survival.

show abstract

Molecular Genetics of Renal Cell Tumors: A Practical Diagnostic Approach

Cited by 23 publications

References 168 publications

Interaction of RARRES1 with ICAM1 modulates macrophages to suppress the progression of kidney renal clear cell carcinoma

Interaction of RARRES1 with ICAM1 modulates macrophages to suppress the progression of kidney renal clear cell carcinoma

Analysis of miRNA-Mediated ceRNAs In The Pathogenesis of Renal Cell Carcinoma: An In Silico Approach

Early Occurrence of Two Distinct Histological Types of Renal Cell Carcinoma in End-Stage Renal Disease Patient on Haemodialysis

Contact Info

Product

Resources

About